A Phase II, Open-label, Multi-Center Study to Evaluate the Efficacy of 90Y-SMT 487 Administered Intravenously to Patients With Refractory Small Cell Lung or Advanced Metastatic Breast Cancer Expressing Somatostatin Receptors as Determined by OctreoScan Scintigraphy
OBJECTIVES: I. Determine the tumor response rate of yttrium Y 90 SMT 487 in patients with
refractory small cell lung cancer or advanced metastatic breast cancer expressing
somatostatin receptor. II. Determine the safety of this treatment regimen in these patients.
III. Determine the overall survival of these patients with this treatment regimen. IV.
Determine the quality of life in these patients with this treatment regimen. V. Determine
the frequency of tumors which are positive (3+ or 4+) for OctreoScan scintigraphy in this
OUTLINE: This is a multicenter study. Patients receive yttrium Y 90 SMT 487 IV over 10-15
minutes on day 1. Treatment repeats every 6-9 weeks for up to 3 courses in the absence of
unacceptable toxicity or disease progression. Quality of life is assessed at baseline and at
course 3, week 6. Patients are followed at 6 and 12 months.
PROJECTED ACCRUAL: A total of 10-29 patients will be accrued for this study.
Primary Purpose: Treatment
Larry K. Kvols, MD
H. Lee Moffitt Cancer Center and Research Institute
United States: Federal Government
|H. Lee Moffitt Cancer Center and Research Institute||Tampa, Florida 33612|